Magna-Lab (OTCMKTS:MAGAA) and Stereotaxis (OTCMKTS:STXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Magna-Lab and Stereotaxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Magna-Lab N/A N/A -4,533.33%
Stereotaxis -14.80% -1,456.01% -20.71%

Analyst Ratings

This is a summary of current recommendations for Magna-Lab and Stereotaxis, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Magna-Lab 0 0 0 0 N/A
Stereotaxis 0 0 0 0 N/A

Institutional & Insider Ownership

20.8% of Stereotaxis shares are owned by institutional investors. 15.3% of Magna-Lab shares are owned by company insiders. Comparatively, 34.9% of Stereotaxis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Magna-Lab and Stereotaxis’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Magna-Lab N/A N/A -$150,000.00 N/A N/A
Stereotaxis $29.35 million 8.75 $120,000.00 N/A N/A

Stereotaxis has higher revenue and earnings than Magna-Lab.

Volatility and Risk

Magna-Lab has a beta of 5.81, indicating that its stock price is 481% more volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Summary

Stereotaxis beats Magna-Lab on 5 of the 8 factors compared between the two stocks.

About Magna-Lab

Magna-Lab, Inc. is a shell company, which intends to identify and merge with an operating company. The company was founded by Lawrence A. Minkoff on February 22, 1991 and is headquartered in Syosset, NY.

About Stereotaxis

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.

Receive News & Ratings for Magna-Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magna-Lab and related companies with MarketBeat.com's FREE daily email newsletter.